5-amino-1MQ
5-amino-1MQ is not a peptide. It is a small molecule that blocks an enzyme involved in NAD+ metabolism. The mouse data is genuinely interesting and there are no human trials at all.
- Legal lane: not FDA-approved. Sold as a research chemical.
- Evidence grade: D (no human data)
- Form: oral capsule, and sold as an injection
- Sport: prohibited, in the category for substances no regulator has approved
What it is
NNMT, nicotinamide N-methyltransferase, consumes nicotinamide (a form of vitamin B3) and a methyl donor called SAM. 5-amino-1MQ blocks it. The theory is that blocking NNMT leaves more nicotinamide available to make NAD+, and more SAM for everything else that needs methyl groups.
Because it acts on an enzyme rather than a receptor, it is dosed in milligrams rather than the micrograms typical of peptides.
What the evidence shows
- The foundational 2018 study by Neelakantan and colleagues characterized it as a selective NNMT inhibitor and showed fat loss in diet-induced obese mice.
- In those mice, body weight and fat mass fell without a change in how much they ate, and glucose tolerance improved.
- Muscle findings appeared only in aged or injured animals, not healthy ones.
- ClinicalTrials.gov lists no registered trial of 5-amino-1MQ, or of any NNMT inhibitor, in humans. Nothing has been published.
Worth contrasting: NMN and NR, the other NAD+-pathway compounds people take, have completed early-phase human trials with published pharmacokinetics. This one has not.
Legal status
Not FDA-approved for anything. It is not a peptide, so some of the 2026 peptide compounding changes do not apply to it. Sources disagree about whether pharmacies are dispensing it; some clinic sites advertise it as compounded while the independent reviews say it is not available by prescription. Verify directly rather than trusting either.
Reported dosing
No dose has been established in human trials.
The figures in circulation are 50 to 150 mg a day orally, commonly from 50 mg capsules. For the injectable version the reported range spans roughly 150 micrograms to 100 mg a day, a 40-fold spread, which tells you how little agreement exists. None of it comes from a study in people.
Safety
- No human safety data exists. Reproductive and developmental toxicology has not been done.
- NNMT's byproduct, 1-methylnicotinamide, has biological activity of its own, so suppressing its production is not necessarily neutral.
- Stacking it with NMN or NR changes the balance between NAD+ and methyl groups in ways nobody has characterized in humans.